Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen MacKay

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 25, 2012
Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'Thomas Walter, Anne M Horgan, Mairead McNamara, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2012
Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective studyThomas Walter, Anne M Horgan, Mairead McNamara, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancerHelen Mackay, David Hedley, Pierre Major, et al.
Cancer|December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancerBobbie J Rimel, Danielle Enserro, David P Bender, et al.
International Journal of Radiation Oncology, Biology, Physics|November 9, 2015
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical StudyMichael F Milosevic, Carol A Townsley, Naz Chaudary, et al.
Targeted Oncology|August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric CancersBernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|December 28, 2023
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in CanadaKaren Gambaro, Mélanie Groleau, Suzan McNamara, et al.
BMC Cancer|December 20, 2014
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomasAlicia A Tone, Melissa K McConechy, Winnie Yang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 29, 2025
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 ImmunotherapyRamez Eskander, Jung-Yun Lee, Mansoor Mirza, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|December 25, 2012
Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'Thomas Walter, Anne M Horgan, Mairead McNamara, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2012
Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective studyThomas Walter, Anne M Horgan, Mairead McNamara, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancerHelen Mackay, David Hedley, Pierre Major, et al.
Cancer|December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancerBobbie J Rimel, Danielle Enserro, David P Bender, et al.
International Journal of Radiation Oncology, Biology, Physics|November 9, 2015
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical StudyMichael F Milosevic, Carol A Townsley, Naz Chaudary, et al.
Targeted Oncology|August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric CancersBernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|December 28, 2023
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in CanadaKaren Gambaro, Mélanie Groleau, Suzan McNamara, et al.
BMC Cancer|December 20, 2014
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomasAlicia A Tone, Melissa K McConechy, Winnie Yang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 29, 2025
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 ImmunotherapyRamez Eskander, Jung-Yun Lee, Mansoor Mirza, et al.
Pageof 7